Home / FlashMed


Titolo Fibroblast Growth Factor 23 and Sudden Versus Non-sudden Cardiac Death: The Cardiovascular Health Study
Autore Rajat Deo, MD, MTR,1 Ronit Katz, DPhil,2 Ian H. de Boer, MD, MS,2,3 Nona Sotoodehnia, MD, MPH,4 Bryan Kestenbaum, MD, MS,2,3 Kenneth J. Mukamal, MD,5 Michel Chonchol, MD,6 Mark J. Sarnak, MD, MS,7 David Siscovick, MD, MPH,8,9,10,11,12 Michael G. Shlipak, MD, MPH,13,14,15,16 and Joachim H. Ix, MD, MAS17,18
Referenza Am J Kidney Dis. 2015, dx.doi.org/10.1053/j.ajkd.2014.10.025.

Background: Elevated fibroblast growth factor 23 (FGF-23) concentrations are associated with greater risk of cardiovascular events and mortality, especially among people with chronic kidney disease (CKD). Because individuals with CKD are at an increased risk of sudden cardiac death (SCD), we sought to understand whether FGF-23 level is a stronger risk factor for SCD versus non-SCD.

Study Design: Cohort study.

Setting & Participants: 3,244 participants 65 years or older in the community-based Cardiovascular

Health Study.

Predictor: Plasma FGF-23 concentrations.

Outcomes: We assessed SCD and non-SCD in these analyses. SCD was adjudicated rigorously and was defined as a sudden pulseless condition of cardiac origin in a previously stable person occurring out of hospital or in the emergency department.

Measurements: We estimated associations of baseline FGF-23 concentrations with SCD and non-SCD using Cox proportional hazards models after adjustment for demographics, cardiovascular risk factors, comorbid conditions, and kidney function. We also tested whether associations differed by CKD status.

Results: During a median follow-up of 8.1 years, there were 118 adjudicated SCD and 570 non-SCD events. After multivariable adjustment for demographics, cardiovascular risk factors, comorbid conditions, and parameters of kidney function, higher FGF-23 concentrations were an independent risk factor for non-SCD (HR [per doubling], 1.17; 95% CI, 1.06-1.30). However, elevated FGF-23 concentrations were not associated independently with SCD (HR [per doubling], 1.07; 95% CI, 0.85-1.35). In stratified analysis byCKD status (36.5% of cohort), doubling of FGF-23 concentrations was associated independently with non-SCD (adjusted HR, 1.26; 95% CI, 1.10-1.45). A similar magnitude of association was observed between FGF-23 level and SCD in the CKD subgroup; however, it was not significant (HR, 1.20; 95% CI, 0.89-1.62).

Limitations: Limited power to detect moderate-sized effects between FGF-23 level and SCD in both the primary and stratified analyses.

Conclusions: In this population-based study, FGF-23 level elevations were associated independently with non- SCD. Among individuals with CKD, the associations between FGF-23 level and SCD and non-SCD were similar.

Data 17.03.2015
Maggiori informazioni   
Lista completa